Calmerry vs Danaher Corporation
Side-by-side comparison of AI visibility scores, market position, and capabilities
Subscription online therapy via text, video, and audio; accessible pricing for patients managing anxiety and depression; therapist matching with easy switching based on preference selection.
About
Calmerry is an online therapy platform that connects individuals with licensed therapists for mental health support through a subscription model covering text messaging, live video sessions, and audio calls. The platform focuses on accessibility and affordability, offering therapy to users who face barriers of cost, stigma, or geographic access to traditional in-person care. Calmerry matches clients to therapists based on their presenting concerns, preferences, and therapist specialization, with the ability to switch therapists if the initial match is not a good fit. The platform serves a primarily direct-to-consumer audience, individuals managing anxiety, depression, relationship issues, stress, and other mental health concerns. Calmerry competes with BetterHelp and Talkspace in the online therapy market, differentiating through competitive pricing and a straightforward subscription structure. The company has grown rapidly as awareness of teletherapy has expanded following the COVID-19 pandemic, which accelerated consumer acceptance of remote mental healthcare.
Washington DC life sciences instruments (NYSE: DHR) at $23.9B FY2024 revenue; Cytiva bioprocessing, Beckman Coulter diagnostics, biopharma destocking recovery, 2025 core revenue +3% guidance competing with Thermo Fisher.
About
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, manufacturing, and marketing analytical instruments, reagents, consumables, software, and services for life sciences research, clinical diagnostics, and environmental monitoring through approximately 65,000 employees worldwide. In fiscal year 2024, Danaher reported revenues of $23.9 billion (flat year-over-year) with non-GAAP core revenue declining 1% as the biopharma sector's inventory destocking cycle continued, with Q4 2024 revenue of $6.5 billion (+2.0% reported, +1.0% core) representing an inflection toward recovery, generating $6.7 billion in operating cash flow and $5.3 billion in free cash flow. Danaher guided 2025 core revenue growth of approximately 3% — marking the expected return to growth as biopharma customers who destocked pandemic-era bioprocessing supply surpluses return to normalized purchasing. CEO Rainer Blair leads Danaher's post-spinoff strategy: in September 2023, Danaher separated its Environmental & Applied Solutions segment as Veralto Corporation (NYSE: VLTO), creating two independent public companies — Danaher (pure-play life sciences and diagnostics) and Veralto (water quality and product identification). Danaher's current portfolio centers on bioprocessing (Cytiva's bioreactors, membranes, single-use manufacturing for drug production), clinical diagnostics (Beckman Coulter chemistry and hematology analyzers, Radiometer blood gas analyzers, Cepheid molecular diagnostics), and life sciences research instruments (SCIEX mass spectrometry, Leica Microsystems microscopy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.